Wordt geladen...
PCI-32765, the First BTK (Bruton’s Tyrosine Kinase) Inhibitor in Clinical Trials
Ibrutinib is a potent covalent kinase inhibitor that targets BTK. BTK, or Bruton’s tyrosine kinase, is an obvious target for therapy of B cell diseases because inactivating mutations lead to B cell aplasia in humans and the disease X-linked agammaglobulinemia. Ibrutinib has modest cytotoxicity again...
Bewaard in:
| Hoofdauteur: | |
|---|---|
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
2013
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3584329/ https://ncbi.nlm.nih.gov/pubmed/23296407 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11899-012-0147-9 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|